Alzamend Neuro (NASDAQ:ALZN) Issues Earnings Results, Misses Estimates By $0.12 EPS

Alzamend Neuro (NASDAQ:ALZN) posted its quarterly earnings results on Thursday. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.12), FiscalAI reports.

Alzamend Neuro Trading Up 1.2%

NASDAQ ALZN traded up $0.02 during trading on Thursday, hitting $1.70. 8,710 shares of the company’s stock were exchanged, compared to its average volume of 126,647. Alzamend Neuro has a fifty-two week low of $0.84 and a fifty-two week high of $2.68. The company has a market cap of $8.21 million, a PE ratio of -0.59 and a beta of 0.23. The stock’s 50 day moving average price is $1.42 and its two-hundred day moving average price is $1.37.

Hedge Funds Weigh In On Alzamend Neuro

An institutional investor recently raised its position in Alzamend Neuro stock. Geode Capital Management LLC grew its holdings in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) by 33.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 27,506 shares of the company’s stock after acquiring an additional 6,928 shares during the period. Geode Capital Management LLC owned 0.72% of Alzamend Neuro worth $50,000 as of its most recent SEC filing. 49.61% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of Alzamend Neuro from a “sell (e)” rating to a “sell (e+)” rating in a report on Monday, August 31st. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $28.00.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.